Matches in Wikidata for { <http://www.wikidata.org/entity/Q64149845> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q64149845 description "clinical trial" @default.
- Q64149845 description "ensayu clínicu" @default.
- Q64149845 description "klinisch onderzoek" @default.
- Q64149845 description "клінічне випробування" @default.
- Q64149845 name "Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients" @default.
- Q64149845 type Item @default.
- Q64149845 label "Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients" @default.
- Q64149845 prefLabel "Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients" @default.
- Q64149845 P1050 Q64149845-1CCA786F-2483-45AC-8B27-F595612EBE43 @default.
- Q64149845 P1132 Q64149845-746A6E2D-1166-477E-8F2D-9F3E3BBB5AA2 @default.
- Q64149845 P1476 Q64149845-23BBBFA0-FEF8-4818-9198-F9A8FF181504 @default.
- Q64149845 P17 Q64149845-0C2ED07C-2133-4094-9117-11F9E8F265E7 @default.
- Q64149845 P17 Q64149845-1A8DB66E-E61D-4502-A31A-4567D503384A @default.
- Q64149845 P17 Q64149845-34CE10DB-D3F7-45FA-B62B-058C6F71A4B8 @default.
- Q64149845 P17 Q64149845-3E0A8BF2-41B7-475D-B74C-CC7EDB88B32A @default.
- Q64149845 P17 Q64149845-51A9130A-E9E4-48D5-909B-D184CA67493D @default.
- Q64149845 P17 Q64149845-53FCCEAE-343D-4C14-B2E3-21BB1E270CAB @default.
- Q64149845 P17 Q64149845-59A8714F-1CEE-4014-BDCC-F19E7790A45E @default.
- Q64149845 P17 Q64149845-8C7F014D-AFA3-4C11-B87F-E91C8729C75F @default.
- Q64149845 P17 Q64149845-A7EAAA3E-4ACD-4ECF-99FB-F0F4C7EF6569 @default.
- Q64149845 P17 Q64149845-C6CB97CC-D42D-4588-8E84-9B78CC9E360F @default.
- Q64149845 P17 Q64149845-CF475E68-6BFD-48B1-A323-74D025276914 @default.
- Q64149845 P17 Q64149845-F40862CF-6475-44DB-B0B8-E4868B02251D @default.
- Q64149845 P17 Q64149845-FCF1326F-8D47-4658-9BE9-179F076397CB @default.
- Q64149845 P1813 Q64149845-8ECFCF91-5A6A-4326-8009-B07F377ACE6F @default.
- Q64149845 P2899 Q64149845-DEFD519D-5BBA-422E-9B66-8ADF3333E321 @default.
- Q64149845 P3098 Q64149845-72C07D92-D333-4E24-BDE6-C5C421288B87 @default.
- Q64149845 P31 Q64149845-C89E49B3-EC7A-46CF-93E0-9D42AA7A3FF4 @default.
- Q64149845 P4844 Q64149845-B07E90C6-FCA9-460A-B620-705E269346AE @default.
- Q64149845 P580 Q64149845-31B98ADE-F710-49AC-AA03-E7894478F77A @default.
- Q64149845 P582 Q64149845-8869A5A2-571C-4B41-9644-442A324E0B92 @default.
- Q64149845 P6099 Q64149845-7752D79A-2B70-4D86-BD4F-6B6DE2FB753C @default.
- Q64149845 P8363 Q64149845-15CD03F3-403A-4CC9-B90A-660984CE5BBC @default.
- Q64149845 P1050 Q467635 @default.
- Q64149845 P1132 "+302" @default.
- Q64149845 P1476 "Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines" @default.
- Q64149845 P17 Q142 @default.
- Q64149845 P17 Q145 @default.
- Q64149845 P17 Q155 @default.
- Q64149845 P17 Q16 @default.
- Q64149845 P17 Q17 @default.
- Q64149845 P17 Q28 @default.
- Q64149845 P17 Q29 @default.
- Q64149845 P17 Q30 @default.
- Q64149845 P17 Q38 @default.
- Q64149845 P17 Q408 @default.
- Q64149845 P17 Q41 @default.
- Q64149845 P17 Q43 @default.
- Q64149845 P17 Q664 @default.
- Q64149845 P1813 "IKEMA" @default.
- Q64149845 P2899 "+18" @default.
- Q64149845 P3098 "NCT03275285" @default.
- Q64149845 P31 Q30612 @default.
- Q64149845 P4844 Q408524 @default.
- Q64149845 P580 "2017-10-25T00:00:00Z" @default.
- Q64149845 P582 "2020-11-01T00:00:00Z" @default.
- Q64149845 P6099 Q42824827 @default.
- Q64149845 P8363 Q78089383 @default.